Exam 2 - Random Multiple Choice

Question 1

JH will receive chemotherapy to shrink a tumor, followed later by surgery. She will receive cisplatin and pemetrexed. What is the term that best describes the timing of JH’s chemotherapy in relation to her surgery?

a. adjuvant
b. adjunct
c. neoadjuvant
d. neoadjunct

Answer 1

c. neoadjuvant

Question 2

GW is a 58-year-old man with metastatic colon cancer who will be starting treatment with irinotecan plus cetuximab therapy. Which of the following is true regarding his treatment?

A. Cetuximab is an oral endothelial growth factor receptor (EGFR) Inhibitor and should not be crushed.
B. Cetuximab is an intravenous EGFR inhibitor.
C. Irinotecan is an oral topoisomerase I Inhibitor and tablets can be split.
D. Irinotecan is an intravenous topoisomerase II inhibitor.

Answer 2

B. Cetuximab is an intravenous EGFR inhibitor.

Question 3

A 62-year-old woman who quit smoking 15 years ago comes to clinic asking, “Should I undergo screening for lung cancer?” Her past medical history is significant for hypertension and chronic obstructive pulmonary disease (COPD). Her social history is significant for a 31-pack year history of smoking and drinks a beer or two a day. Which of the following represent appropriate lung cancer screening recommendations for this patient?

A. Annual chest magnetic resonance imaging (MRI)
B. Annual chest X-ray
C. Annual sputum cytology
D. Annual helical computed tomography (CT) scan

Answer 3

D. Annual helical computed tomography (CT) scan

Question 4

The goal of neoadjuvant chemotherapy is to:

A. Eradicate micrometastatic disease following localized modalities such as surgery or radiation or both.
B. Attempt to shrink large tumors and make them more amenable to subsequent surgical resection.
C. Reduce the symptoms of the cancer without affecting the underlying tumor.
D. Rapidly treat and reduce tumor volume for a cure without other treatment modalities

Answer 4

B. Attempt to shrink large tumors and make them more amenable to subsequent surgical resection.

Question 5

Which of the following monoclonal antibodies exerts its anticancer effects by binding to the vascular endothelial growth factor (VEGF) receptor?

A. Nivolumab
B. Bevacizumab
C. Ramucirumab
D. Durvalumab

Answer 5

C. Ramucirumab

(a. binds to PD-1 receptor; c. binds to VEGF directly; d. binds to PD-1 ligand found on tumor cells)